Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 5911-5923

  Simpkins, Fiona ^a,b   Hevia Paez, Pedro ^a   Sun, Jun ^a   Ullmer, Wendy ^a   Gilbert, Candace A ^a   Da Silva, Thiago ^a   Pedram, Ali ^d   Levin, Ellis R ^d   Reis, Isildinha M ^a   Rabinovich, Brian ^e   Azzam, Diana ^a   Xu, Xiang Xi ^b   Ince, Tan A ^a,c   Yang, Ji Yeon ^e   Verhaak, Roel G W ^e   Lu, Yiling ^e   Mills, Gordon B ^e   Slingerland, Joyce M ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MYC PROTEIN; PROTEIN P27; PROTEIN TYROSINE KINASE; SARACATINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DRUG BINDING; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; FOSL1 GENE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOGENESIS; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; OVARY CANCER; PHARMACOLOGICAL BLOCKING; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEINASE INHIBITION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIOXOLES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; OVARIAN NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; QUINAZOLINES; RECEPTORS, ESTROGEN; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868587857     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1257     Document Type: Article

References (54)

1. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol 2005;3:723-36. (Pubitemid 41823989)
2. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF, et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 1994;50:131-5. (Pubitemid 24265224)
3. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF, et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 1994;30A:682-6. (Pubitemid 24164260)
4. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, et al. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 2009;15:2971-8.
5. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005;12:851-66. (Pubitemid 41815780)
6. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 2008;111:144-51.
7. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
8. Rao BR, Slotman BJ. Endocrine role in ovarian cancer. Endocr Relat Cancer 1996;3:309-26. (Pubitemid 27046604)
9. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 2002;84:201-9. (Pubitemid 34139799)
10. Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, et al. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol 2009;113:205-9.
11. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer 2008;18:600-14. (Pubitemid 352020164)
12. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000;97:9042-6. (Pubitemid 30626670)
13. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-67. (Pubitemid 351430863)
14. Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB, et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007;128:269-80. (Pubitemid 46123508)
15. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007;128:281-94. (Pubitemid 46123510)
16. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 2001;20:6050-9. (Pubitemid 33049280)
17. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-81.
18. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609. (Pubitemid 28034534)
19. Le XF, Bast RCJr. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 2011;12:260-9.
20. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, et al. Activated SRC protein tyrosine kinase is overexpressed in latestage human ovarian cancers. Gynecol Oncol 2003;88:73-9. (Pubitemid 36062670)
21. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998;17:2008-18. (Pubitemid 28154530)
22. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, et al. Combined Src and Aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009;15:3396-405.
23. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo . Breast Cancer Res Treat 2011;128:69-78.
24. Ple PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 2004;47:871-87. (Pubitemid 38176790)
25. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009;3:248-61.
26. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010;16:4876-83.
27. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007;282:22278-88. (Pubitemid 47267344)
28. Pedram A, Razandi M, Deschenes RJ, Levin ER. DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell 2012;23:188-99.
29. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 2008;105:14342-6.
30. Sun J, Nawaz Z, Slingerland JM. Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen responsive elements in breast cancer cells. Mol Endocrinol 2007;21:2651-62. (Pubitemid 350035148)
31. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010;6:129-51.
32. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
33. Hayward SW, Del BR, Deshpande N, Hall PA. A functional model of adult human prostate epithelium. The role of androgens and stroma in architectural organisation and the maintenance of differentiated secretory function. J Cell Sci 1992;102:361-72.
34. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96:48-55. (Pubitemid 39612416)
35. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA, et al. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 1989;63:280-8. (Pubitemid 19035019)
36. Wong AS, Kim SO, Leung PC, Auersperg N, Pelech SL. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 2001;82:305-11. (Pubitemid 32730608)
37. Talapatra S, Thompson CB. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 2001;298:873-8. (Pubitemid 32761898)
38. Fazekas AG, MacFarlane JK. Studies on cytosol and nuclear binding of estradiol in human breast cancer. J Steroid Biochem 1980;13:613-22. (Pubitemid 11237277)
39. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 2000;43:4934-47. (Pubitemid 32040974)
40. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999;140:800-4. (Pubitemid 29058215)
41. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001;44:4230-51. (Pubitemid 33095330)
42. Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, Katzenellenbogen BS, et al. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem 2004;47:5872-93. (Pubitemid 39507333)
43. Hwang KA, Park SH, Yi BR, Choi KC. Gene alterations of ovarian cancer cells expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. Lab Anim Res 2011;27:99-107.
44. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439-48. (Pubitemid 40780556)
45. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8.
46. Coleman J, Xiang Y, Pande P, Shen D, Gatica D, Patton WF. A live-cell fluorescence microplate assay suitable for monitoring vacuolation arising from drug or toxic agent treatment. J Biomol Screen 2010;15:398-405.
47. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 2001;8:588-94. (Pubitemid 32586595)
48. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, et al. The role of p27 (Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 2011;103:1403-22.
49. Migliaccio A, DiDomenico M, Castona C, DeFalco A, Bontempo P, Nola E, et al. Tyrosine kinas/p21ras/MAP-kinase pathway activation by estradiol receptor complex in MCF-7 cells. EMBO J 1996;15: 1292-300.
50. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998;58:5367-73. (Pubitemid 28551118)
51. Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006;5:3023-31. (Pubitemid 46092043)
52. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
53. van Delft MF, Smith DP, Lahoud MH, Huang DC, Adams JM. Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death Differ 2010;17:821-32.
54. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010;116:4980-90.